Natural product therapy for Glaucoma:  Isorhapontigenin, isolated from Genetum and Norway spruce (Picea abies), and sitka spruce (Picea sitchensis), among others, increases Nmnat1 expression, increases NAD+ levels, improves neuroanl dysfunction, and protects against glaucoma via down regulation of its target gene, 17/October/2017, 11.34 pm

Natural product-derived therapy for Stroke: Glabridin, isolated from Licorice/Glycyrrhiza glabra L, which is used as a food additive (Sweetener), attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits via up regulation of its target genes BDNF and NAMPT, 17/October/2017, 11. 23 pm
October 17, 2017
Natural product-derived therapy for anxiety and depression: Artesunate, isolated from Artemisia annua L among others, decreases PHF8 levels, increases the expression of serotonin receptors Htr1a and Htr2a, and promotes resistance to stress-induced -anxiety and -depression via down regulation of its target gene, 17/October/2017, 11.40 pm
October 17, 2017
Show all

Introduction: What they say

A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes Medical Institute, Bar Harbor, ME 04609, USA shows that “Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.” This research paper was published, in the 9 February 2017 issue of the journal “Science” [One of the best research journals in “General science” with an I.F of 34.661], by Prof. Simon W. M. John and Pete A. Williams and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product therapy for Glaucoma:  Isorhapontigenin, isolated from Genetum and Norway spruce (Picea abies), and sitka spruce (Picea sitchensis), among others, increases Nmnat1 expression, increases NAD+ levels, improves neuroanl dysfunction, and protects against glaucoma via down regulation of its target gene

price-quote[easy_payment currency=”USD”]


From significance of the study to public health relevance:

Given that: (1) Glaucoma is a neurodegenerative disease; (2) more than 80 million people worldwide are affected by Glaucoma; (2) Glaucoma is the second leading cause of blindness; (3) Glucosma has no cure; (4) vision lost due to glaucoma is irreversible; (5) the global economic cost spent for Glaucoma treatment is enormous, there is an urgent need to find: (i) a way to induce regeneration of ganglion cells that were lost in Glaucoma; (ii) a cheaper alternative to the existing expensive anti-glaucoma drugs; (iii) a side-effect-free natural product-based drug; and (v) a way to cure, not just treat, Glaucoma permanently.


What is known?

Prof.Simon’s research team has recently shown that:(1) glaucoma-prone mice suffer from mitochondrial abnormalities, resulting in neuronal dysfunction; (2) NAD+ levels decrease with age; (3) administration of Niacin/Vitamin-B3 protects against glaucoma; (4) expression of Nmnat1, a key NAD+-producing enzyme, protects against glaucoma, suggesting that increasing the expression of Nmnat1 in glaucoma patients may alleviate glaucoma.


From research findings to Therapeutic opportunity:

Figure 1. Mechanistic insights into how Isorhapontigenin alleviates glucoma. Isorhapontigenin, by increasing the expression of its target gene, enhances NAD+ levels and improves glaucoma

This study suggests, for the first time, a natural product based therapy for Glaucoma. Isorhapontigenin, by increasing the expression of its target gene, it may increase the expression of Nmnat1. Thereby, it may: (1) increase NAD+ levels; (2) decrease Intraocular pressure; (3) improve pressure-induced damage; and (4) alleviate glaucoma (Fig.1). Thus, pharmacological formulations encompassing “Isorhapontigenin or its analogs,  either alone or in combination with other drugs,” may be used to treat Glaucoma.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Isorhapontigenin increase the levels of NAD+ to prevent glaucoma?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Natural product therapy for Glaucoma:  Isorhapontigenin, isolated from Genetum and Norway spruce (Picea abies), and sitka spruce (Picea sitchensis), among others, increases Nmnat1 expression, increases NAD+ levels, improves neuroanl dysfunction, and protects against glaucoma via down regulation of its target gene, 17/October/2017, 11.33 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.